Ad Header



The Pulse of the Pharmaceutical Industry

FDA Accepts BPL’s Amended BLA Submission for Coagadex® (Coagulation Factor X, Human)

Written by: | | Dated: Wednesday, May 27th, 2015

ELSTREE, U.K. & DURHAM, N.C.–(BUSINESS WIRE)–Bio Products Laboratory, Ltd. (BPL), a leading manufacturer of plasma-derived therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s amended Biologics License Application for Coagadex® for hereditary factor X deficiency. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 27, 2015.

Coagadex is an investigational, high purity human factor X concentrate that has received FDA orphan drug designation for the treatment of hereditary factor X deficiency. The FDA is currently reviewing data from two Phase III trials of Coagadex.

Hereditary factor X deficiency is a rare bleeding disorder that affects approximately 400-600 patients in the United States. Affected individuals often have inadequate amounts of circulating factor X, an important component of the coagulation system. Factor X deficient patients are at increased risk of bleeding and need to be managed similarly to hemophilia patients. There is currently no factor X product specifically approved by the FDA for the treatment of patients with hereditary factor X deficiency.

In addition, BPL has submitted a Marketing Authorization Application to the European Medicines Agency that is also currently under review.

About Bio Products Laboratory, Ltd.

Bio Products Laboratory, Ltd. (BPL) is a leading manufacturer of plasma-derived protein therapies with global headquarters in Elstree, England, US headquarters in Durham, NC, and a presence in more than 45 countries worldwide. The company has over 60 years of experience developing and manufacturing plasma-derived therapies since being established as part of the Lister Institute in 1950, and currently markets a wide range of products including coagulation factors, human immunoglobulins, and albumin. BPL is committed to continued investment in research and development to maintain its key position as a reliable supplier of high-quality products to patients and healthcare providers worldwide.


Source: Business Wire Health

Leave a Reply

Be the First to Comment!

Notify of


Ad Right Top


August 16 Cover

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact customer service at

August 2016 Focus: Top 200 Medicines, Lions Health 2016, Pharma Leaders of Innovation


Ad Right Bottom

Password Reset
Please enter your e-mail address. You will receive a new password via e-mail.

Main Navigation